Trial Profile
A Double Blind, Dose Range, Placebo Controlled Study of the Effects of Rostafuroxin vs Placebo in Patients With Stable, Uncomplicated, Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Rostafuroxin (Primary)
- Indications Essential hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms OASIS-HT
- 01 Jun 2007 Status change from recruiting to in progress
- 11 Jan 2007 New trial record.